Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development
I'm LongbridgeAI, I can summarize articles.Zura Bio highlighted tibulizumab, a dual IL-17/BAFF bispecific antibody in Phase 2 development for immune-mediated diseases. Topline data for hidradenitis suppurativa is targeted for Q4 2026, and systemic sclerosis for 1H 2027. A polymyalgia rheumatica study is planned to start by year-end 2026. The Phase 1/1b program dosed 78 participants with high target engagement. Cash runway extends through at least year-end 2028.
- Zura Bio highlighted tibulizumab, a bispecific antibody designed to inhibit IL-17 and BAFF across multiple immune-mediated diseases. * Phase 2 hidradenitis suppurativa topline data targeted for Q4 2026; systemic sclerosis topline data expected in 1H 2027. * Polymyalgia rheumatica Phase 2 study planned to start by year-end 2026. * Phase 1/1b program dosed 78 participants; median trough target engagement exceeded 98% for IL-17 and BAFF at 300 mg Q4W. * Cash runway projected through at least year-end 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here